Charles River Laboratories’ (CRL) Research Models and Services (RMS) business continues to benefit from the Charles River Accelerator and Development Labs (CRADL) initiative. Yet, the global business environment remains challenging, denting the company’s growth. The stock carries a Zacks Rank #3 (Hold).RMS business services are in high demand among the company’s clients in the field of basic research and screening of non-clinical drug candidates. These service offerings provide greater flexibility for clien ...